Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms - PubMed
3 hours ago
- #immunotherapy
- #nanoplatforms
- #gastric-cancer
- Overcoming resistance to immune checkpoint blockade (ICB) therapy in gastric cancer (GC) is a major clinical challenge.
- Multi-omics profiling identifies YAP1 as a key regulator of immunosuppressive cellular communities contributing to ICB non-responsiveness.
- Macrophage-membrane-camouflaged hollow mesoporous silica nanoparticles (M@O-VNPs) co-loaded with verteporfin and oxaliplatin are developed to mitigate off-target toxicity.
- M@O-VNPs selectively inhibit YAP1, suppress the CXCL5-CXCR2 axis, and reduce SPP1+ macrophage activity.
- M@O-VNPs induce immunogenic cell death, remodel the tumor microenvironment, and enhance ICB efficacy while minimizing systemic toxicity.
- Synergistic antitumor effects of M@O-VNPs combined with anti-PD-1 therapy are demonstrated in GC models.